- Record: found
- Abstract: found
- Article: not found
Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
Laurent Vroonen
1 ,
Marie-Lise Jaffrain-Rea ,
Patrick Petrossians ,
Gianluca Tamagno ,
Philippe Chanson ,
Lucio Vilar ,
Françoise Borson-Chazot ,
Luciana A Naves ,
Thierry Brue ,
Blandine Gatta ,
Brigitte Delemer ,
Enrica Ciccarelli ,
Paolo Beck-Peccoz ,
Philippe Caron ,
Adrian F Daly ,
Albert Beckers
Nov 2012
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Dopamine agonist resistance in prolactinoma is an infrequent phenomenon. Doses of cabergoline (CAB) of up to 2.0 mg/week are usually effective in controlling prolactin (PRL) secretion and reducing tumor size in prolactinomas. The clinical presentation, management, and outcome of patients that are not well controlled by such commonly used doses of CAB-resistant patients are poorly understood.